Gonadotropins and the Importance of Glycosylation

Post-translational Modification of Protein Biopharmaceuticals

Volumn , Issue , 2009, Pages 109-147

  Ulloa Aguirre, Alfredo ^a   Dias, James A ^b   Bousfield, George R ^c  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c WICHITA STATE UNIVERSITY   (United States)

Author keywords

Glycans; Glycoprotein hormones; Glycosylation; Gonadotropins; Therapeutics

Indexed keywords

EID: 77649181259     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527626601.ch5     Document Type: Chapter

References (253)

1. Pierce, J.G. and Parsons, T.F. (1979). Glycoprotein hormones: similar molecules with different functions. UCLA Forum in Medical Sciences, 21, 99-117.
2. Pierce, J.G. and Parsons, T.F. (1981). Glycoprotein hormones: structure and function. Annual Review of Biochemistry, 50, 465-495.
3. Ulloa-Aguirre, A. and Timossi, C. (2000). Biochemical and functional aspects of gonadotrophin-releasing hormone and gonadotrophins. Reproductive Biomedicine Online, 1, 48-62.
4. Ulloa-Aguirre, A. et al. (2001). Endocrine regulation of gonadotropin glycosylation. Archives of Medical Research, 32, 520-532.
5. Birken, S. et al. (1996). Isolation and characterization of human pituitary chorionic gonadotropin. Endocrinology, 137, 1402-1411.
6. Bousfield, G.R. et al. (1996). Structural features of mammalian gonadotropins. Molecular and Cellular Endocrinology, 125, 3-19.
7. Sun, L. et al. (2006). FSH directly regulates bone mass. Cell, 125, 247-260.
8. Meduri, G. et al. (2002) Folliclestimulating hormone receptors in oocytes? The Journal of Clinical Endocrinology and Metabolism, 87, 2266-2276.
9. Ulloa-Aguirre, A. and Conn, P.M. (1998) G protein-coupled receptors and the G protein family, in Handbook of Physiology-Endocrinology (ed. P.M. Conn), Oxford University Press, New York, Section 7, Cellular Endocrinology, pp. 87-141.
10. Ulloa-Aguirre, A. et al. (1999). Structureactivity relationships ofGprotein-coupled receptors. Archives ofMedical Research, 30, 420-435.
11. Ulloa-Aguirre, A. and Timossi, C. (1998). Structure-function relationship of folliclestimulating hormone and its receptor. Human Reproduction Update, 4, 260-283.
12. Khan, H., Yarney, T.A. and Sairam, M.R. (1993). Cloning of alternately spliced mRNA transcripts coding for variants of ovine testicular follitropin receptor lacking the G protein coupling domains. Biochemical and Biophysical Research Communications, 190, 888-894.
13. Li, Y. et al. (2007). FSH stimulates ovarian cancer cell growth by action on growth factor variant receptor. Molecular and Cellular Endocrinology, 267, 26-37.
14. Iqbal, J. et al. (2006). Follicle-stimulating hormone stimulates TNF production from immune cells to enhance osteoblast and osteoclast formation. Proceedings of the National Academy of Sciences of the United States of America, 103, 14925-14930.
15. Richards, J.S. et al. (2002). Novel signaling pathways that control ovarian follicular development, ovulation, and luteinization. Recent Progress in Hormone Research, 57, 195-220.
16. Ulloa-Aguirre, A. et al. (2007). Multiple facets of follicle-stimulating hormone receptor function. Endocrine, 32, 251-263.
17. Uribe, A. et al. (2008). Functional and structural roles of conserved cysteine residues in the carboxyl-terminal domain of the follicle-stimulating hormone receptor in human embryonic kidney 293 cells. Biology of Reproduction, 78, 869-882.
18. Gharib, S.D. et al. (1990). Molecular biology of the pituitary gonadotropins. Endocrine Reviews, 11, 177-199.
19. Fiddes, J.C. and Talmadge, K. (1984). Structure, expression, and evolution of the genes for the human glycoprotein hormones. Recent Progress in Hormone Research, 40, 43-78.
20. Albanese, C. et al. (1996) The gonadotropin genes: evolution of distinct mechanisms for hormonal control. Recent Progress in Hormone Research, 51, 23-58, discussion 59-61.
21. Gordon, D.F., Wood, W.M. and Ridgway, E.C. (1988). Organization and nucleotide sequence of the mouse alpha-subunit gene of the pituitary glycoprotein hormones. DNA, 7, 679-690.
22. Mercer, J.E. and Chin, W.W. (1995). Regulation of pituitary gonadotrophin gene expression. Human Reproduction Update, 1, 363-384.
23. Pierce, J.G. et al. (1971). Biologically active hormones prepared by recombination of the alpha chain of human chorionic gonadotropin and the hormone-specific chain of bovine thyrotropin or of bovine luteinizing hormone. The Journal of Biological Chemistry, 246, 2321-2324.
24. Dias, J.A. and Van Roey, P. (2001). Structural biology of human follitropin and its receptor. Archives of Medical Research, 32, 510-519.
25. Fox, K.M., Dias, J.A. and Van Roey, P. (2001). Three-dimensional structure of human follicle-stimulating hormone. Molecular Endocrinology, 15, 378-389.
26. Lapthorn, A.J. et al. (1994). Crystal structure of human chorionic gonadotropin. Nature, 369, 455-461.
27. Dias, J.A. (2005). Endocrinology: fertility hormone in repose. Nature, 433, 203-204.
28. Walton,W.J. et al. (2001). Characterization of human FSH isoforms reveals a nonglycosylated beta-subunit in addition to the conventional glycosylated betasubunit. The Journal of Clinical Endocrinology and Metabolism, 86, 3675-3685.
29. Balen, A.H. et al. (2004). Pharmacodynamics of a single low dose of long-acting recombinant folliclestimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. The Journal of Clinical Endocrinology and Metabolism, 89, 6297-6304.
30. Fares, F.A. et al. (1992). Design of a longacting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proceedings of the National Academy of Sciences of the United States of America, 89, 4304-4308.
31. LaPolt, P.S. et al. (1992). Enhanced stimulation of follicle maturation and ovulatory potential by long acting folliclestimulating hormone agonists with extended carboxyl-terminal peptides. Endocrinology, 131, 2514-2520.
32. Devroey, P. et al. (2004). Induction of multiple follicular development by a single dose of long-acting recombinant follicle-stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. The Journal of Clinical Endocrinology and Metabolism, 89, 2062-2070.
33. Wu, H. et al. (1994). Structure of human chorionic gonadotropin at 2.6 A resolution from MAD analysis of the selenomethionyl protein. Structure, 2, 545-558.
34. Lustbader, J.W. et al. (1998). Structural and molecular studies of human chorionic gonadotropin and its receptor. Recent Progress in Hormone Research, 53, 395-424.
35. Krystek, S.R. Jr and Dias, J.A. (2005). Glycoprotein hormones tied but not tethered like other cysteine-knot cytokines. Trends in Pharmacological Sciences, 26, 439-442.
36. Sun, P.D. and Davies, D.R. (1995). The cystine-knot growth-factor superfamily. Annual Review of Biophysics and Biomolecular Structure, 24, 269-291.
37. Fan, Q.R. and Hendrickson, W.A. (2005). Structure of human follicle-stimulating hormone in complex with its receptor. Nature, 433, 269-277.
38. Erbel, P.J. et al. (1999). Solution structure of the alpha-subunit of human chorionic gonadotropin. European Journal of Biochemistry, 260, 490-498.
39. Thomas, R.M. et al. (2007). Follicestimulating hormone receptor forms oligomers and shows evidence of carboxyl-terminal proteolytic processing. Endocrinology, 148, 1987-1995.
40. Urizar, E. et al. (2005). Glycoprotein hormone receptors: link between receptor homodimerization and negative cooperativity. EMBO Journal, 24, 1954-1964.
41. Baenziger, J.U. and Green, E.D. (1988). Pituitary glycoprotein hormone oligosaccharides: structure, synthesis and function of the asparagine-linked oligosaccharides on lutropin, follitropin and thyrotropin. Biochimica et Biophysica Acta, 947, 287-306.
42. Parsons, T.F., Bloomfield, G.A. and Pierce, J.G. (1983). Purification of an alternate form of the alpha subunit of the glycoprotein hormones from bovine pituitaries and identification of its O-linked oligosaccharide. The Journal of Biological Chemistry, 258, 240-244.
43. Parsons, T.F. and Pierce, J.G. (1984). Free alpha-like material from bovine pituitaries. Removal of its O-linked oligosaccharide permits combination with lutropin-beta. The Journal of Biological Chemistry, 259, 2662-2666.
44. Blithe, D.L. (1990). N-linked oligosaccharides on free alpha interfere with its ability to combine with human chorionic gonadotropin-beta subunit. The Journal of Biological Chemistry, 265, 21951-21956.
45. Bousfield, G.R. et al. (2007) All-or-noneNglycosylation in primate folliclestimulating hormone beta-subunits. Molecular and Cellular Endocrinology, 260-262, 40-48.
46. Green, E.D., Boime, I. and Baenziger, J.U. (1986). Differential processing of Asnlinked oligosaccharides on pituitary glycoprotein hormones: implications for biologic function. Molecular and Cellular Biochemistry, 72, 81-100.
47. Renwick, A.G. et al. (1987). The asparagine-linked sugar chains of human follicle-stimulating hormone. Journal of Biochemistry, 101, 1209-1221.
48. Green, E.D. and Baenziger, J.U. (1988). Asparagine-linked oligosaccharides on lutropin, follitropin, and thyrotropin. II. Distributions of sulfated and sialylated oligosaccharides on bovine, ovine, and human pituitary glycoprotein hormones. The Journal of Biological Chemistry, 263, 36-44.
49. Green, E.D. and Baenziger, J.U. (1988). Asparagine-linked oligosaccharides on lutropin, follitropin, and thyrotropin. I. Structural elucidation of the sulfated and sialylated oligosaccharides on bovine, ovine, and human pituitary glycoprotein hormones. The Journal of Biological Chemistry, 263, 25-35.
50. Weisshaar, G. et al. (1991). NMR investigations of the N-linked oligosaccharides at individual glycosylation sites of human lutropin. European Journal of Biochemistry, 195, 257-268.
51. Weisshaar, G., Hiyama, J. and Renwick, A.G. (1991). Site-specific N-glycosylation of human chorionic gonadotrophin- structural analysis of glycopeptides by one- and two-dimensional 1H NMR spectroscopy. Glycobiology, 1, 393-404.
52. Dalpathado, D.S. et al. (2006). Comparative glycomics of the glycoprotein follicle stimulating hormone: glycopeptide analysis of isolates from two mammalian species. Biochemistry, 45, 8665-8673.
53. Matzuk, M.M. and Boime, I. (1988). Sitespecific mutagenesis defines the intracellular role of the asparagine-linked oligosaccharides of chorionic gonadotropin beta subunit. The Journal of Biological Chemistry, 263, 17106-17111.
54. Matzuk, M.M. and Boime, I. (1988). The role of the asparagine-linked oligosaccharides of the alpha subunit in the secretion and assembly of human chorionic gonadotrophin. The Journal of Cell Biology, 106, 1049-1059.
55. Matzuk, M.M. and Boime, I. (1989). Mutagenesis and gene transfer define site-specific roles of the gonadotropin oligosaccharides. Biology of Reproduction, 40, 48-53.
56. Matzuk, M.M. et al. (1990). The biological role of the carboxyl-terminal extension of human chorionic gonadotropin [corrected] beta-subunit. Endocrinology, 126, 376-383.
57. Muyan, M. et al. (1998). Dissociation of early folding events from assembly of the human lutropin beta-subunit. Molecular Endocrinology, 12, 1640-1649.
58. Bousfield, G.R. et al. (2008). Chromatofocusing fails to separate hFSH isoforms on the basis of glycan structure. Biochemistry, 47, 1708-1720.
59. Ulloa-Aguirre, A. et al. (1995). Folliclestimulating isohormones: characterization and physiological relevance. Endocrine Reviews, 16, 765-787.
60. Ulloa-Aguirre, A. et al. (1999). Role of glycosylation in function of folliclestimulating hormone. Endocrine, 11, 205-215.
61. Robert, P. (1995) Contribution a l'étude des domaines dínteraction entre les hormones gonadotropes hypophysaires et leurs récepteurs, in Pharmaceutical Sciences, Université René Descartes de Paris, Paris, pp. 101.
62. Helenius, A. and Aebi, M. (2001). Intracellular functions of N-linked glycans. Science, 291, 2364-2369.
63. Damian-Matsumura, P. et al. (1999). Oestrogens regulate pituitary alpha2,3- sialyltransferase messenger ribonucleic acid levels in the female rat. Journal of Molecular Endocrinology, 23, 153-165.
64. Smith, P.L. and Baenziger, J.U. (1988). A pituitary N-acetylgalactosamine transferase that specifically recognizes glycoprotein hormones. Science, 242, 930-933.
65. Smith, P.L. and Baenziger, J.U. (1990). Recognition by the glycoprotein hormone-specific Nacetylgalactosaminetransferase is independent of hormone native conformation. Proceedings of the National Academy of Sciences of the United States of America 87, 7275-7279.
66. Smith, P.L. and Baenziger, J.U. (1992). Molecular basis of recognition by the glycoprotein hormone-specific N-acetylgalactosamine-transferase. Proceedings of the National Academy of Sciences of the United States of America 89, 329-333.
67. Bousfield, G.R. et al. (2000). Carbohydrate analysis of glycoprotein hormones. Methods, 21, 15-39.
68. Dharmesh, S.M. and Baenziger, J.U. (1993). Estrogen modulates expression of the glycosyltransferases that synthesize sulfated oligosaccharides on lutropin. Proceedings of the National Academy of Sciences of the United States of America 90, 11127-11131.
69. Herbert, D.C. (1975). Localization of antisera to LHbeta and FSHbeta in the rat pituitary gland. The American Journal of Anatomy, 144, 379-385.
70. Herbert, D.C. (1976). Immunocytochemical evidence that luteinizing hormone (LH) and follicle stimulating hormone (FSH) are present in the same cell type in the rhesus monkey pituitary gland. Endocrinology, 98, 1554-1557.
71. Bielinska, M., Matzuk, M.M. and Boime, I. (1989). Site-specific processing of the N-linked oligosaccharides of the human chorionic gonadotropin alpha subunit. The Journal of Biological Chemistry, 264, 17113-17118.
72. Corless, C.L. et al. (1987). Gonadotropin alpha subunit. Differential processing of free and combined forms in human trophoblast and transfected mouse cells. The Journal of Biological Chemistry, 262, 14197-14203.
73. Olivares, A. et al. (2000). Reactivity of different LH and FSH standards and preparations in the World Health Organization matched reagents for enzyme-linked immunoassays of gonadotrophins. Human Reproduction, 15, 2285-2291.
74. Stanton, P.G. et al. (1996). Structural and functional characterisation of hFSH and hLH isoforms. Molecular and Cellular Endocrinology, 125, 133-141.
75. Wide, L. and Bakos, O. (1993). More basic forms of both human follicle-stimulating hormone and luteinizing hormone in serum at midcycle compared with the follicular or luteal phase. The Journal of Clinical Endocrinology and Metabolism, 76, 885-889.
76. Baenziger, J.U. (2003). Glycoprotein hormone GalNAc-4-sulphotransferase. Biochemical Society Transactions, 31, 326-330.
77. Schaaf, L. et al. (1997). Glycosylation variants of human TSH selectively activate signal transduction pathways. Molecular and Cellular Endocrinology, 132, 185-194.
78. Nguyen, V.T. et al. (2003). Inositol phosphate stimulation by LH requires the entire alpha Asn56 oligosaccharide. Molecular and Cellular Endocrinology, 199, 73-86.
79. Wide, L. (1985)Median charge and charge heterogeneity of human pituitary FSH, LH and TSH. I. Zone electrophoresis in agarose suspension. Acta Endocrinologica, 109, 181-189.
80. Daya, S. (2002). Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction. Fertility and Sterility, 77, 711-714.
81. Andersen, A.N., Devroey, P. and Arce, J.C. (2006). Clinical outcome following stimulation with highly purified hMG or recombinant FSH in patients undergoing IVF: a randomized assessor-blind controlled trial. Human Reproduction, 21, 3217-3227.
82. Platteau, P. et al. (2006). Similar ovulation rates, but different follicular development with highly purified menotrophin compared with recombinant FSH in WHO Group II anovulatory infertility: a randomized controlled study. Human Reproduction, 21, 1798-1804.
83. Andersen, C.Y., Westergaard, L.G. and van Wely, M. (2004) FSH isoform composition of commercial gonadotrophin preparations: a neglected aspect? Reproductive Biomedicine Online, 9, 231-236.
84. Watanabe, S. et al. (2002). Sialylation of N-glycans on the recombinant proteins expressed by a baculovirusinsect cell system under beta-Nacetylglucosaminidase inhibition. The Journal of Biological Chemistry, 277, 5090-5093.
85. Ulloa-Aguirre, A. et al. (2003). Impact of carbohydrate heterogeneity in function of follicle-stimulating hormone: studies derived from in vitro and in vivo models. Biology of Reproduction, 69, 379-389.
86. Wide, L. (1985). Median charge and charge heterogeneity of human pituitary FSH, LH and TSH. II. Relationship to sex and age. Acta Endocrinologica, 109, 190-197.
87. Padmanabhan, V. et al. (1988). Modulation of serum follicle-stimulating hormone bioactivity and isoform distribution by estrogenic steroids in normal women and in gonadal dysgenesis. The Journal of Clinical Endocrinology and Metabolism, 67, 465-473.
88. Wide, L., Albertsson-Wikland, K. and Phillips, D.J. (1996). More basic isoforms of serum gonadotropins during gonadotropin-releasing hormone agonist therapy in pubertal children. The Journal of Clinical Endocrinology and Metabolism, 81, 216-221.
89. Zambrano, E. et al. (1995). Dynamics of basal and gonadotropin-releasing hormone-releasable serum folliclestimulating hormone charge isoform distribution throughout the human menstrual cycle. The Journal of Clinical Endocrinology and Metabolism, 80, 1647-1656.
90. Ulloa-Aguirre, A. et al. (1995) On the nature of the follicle-stimulating signal delivered to the ovary during exogenously controlled follicular maturation. A search into the immunological and biological attributes and the molecular composition of two preparations of urofollitropin. Archives of Medical Research, 26 Spec No, S219-S230.
91. Ulloa-Aguirre, A., Timossi, C. and Mendez, J.P. (2001). Is there any physiological role for gonadotrophin oligosaccharide heterogeneity in humans? I. Gondatrophins are synthesized and released in multiple molecular forms.Amatter of fact.Human Reproduction, 16, 599-604.
92. Ashwell, G. and Harford, J. (1982). Carbohydrate-specific receptors of the liver. Annual Review of Biochemistry, 51, 531-554.
93. Chappel, S. et al. (1987) Production of bovine follicle stimulating hormone (FSH) by recombinant DNA technology. 69th annual Meeting of the Endocrine Society, Indianapolis, IN, USA,, Abstracts p. 130.
94. Bishop, L.A., Nguyen, T.V. and Schofield, P.R. (1995). Both of the beta-subunit carbohydrate residues of folliclestimulating hormone determine the metabolic clearance rate and in vivo potency. Endocrinology, 136, 2635-2640.
95. Wide, L. and Wide, M. (1984). Higher plasma disappearance rate in the mouse for pituitary follicle-stimulating hormone of young women compared to that of men and elderly women. The Journal of Clinical Endocrinology and Metabolism, 58, 426-429.
96. Timossi, C. et al. (1998). A less acidic human follicle-stimulating hormone preparation induces tissue-type plasminogen activator enzyme activity earlier than a predominantly acidic analogue in phenobarbital-blocked prooestrous rats. Molecular Human Reproduction, 4, 1032-1038.
97. Yding Andersen, C. et al. (1999). FSHinduced resumption of meiosis in mouse oocytes: effect of different isoforms. Molecular Human Reproduction, 5, 726-731.
98. Berger, P. et al. (1993). Variants of human chorionic gonadotropin from pregnant women and tumor patients recognized by monoclonal antibodies. The Journal of Clinical Endocrinology and Metabolism, 77, 347-351.
99. Elliott, M.M. et al. (1997). Carbohydrate and peptide structure of the alpha- and beta-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma. Endocrine, 7, 15-32.
100. Kovalevskaya, G. et al. (1999). Early pregnancy human chorionic gonadotropin (hCG) isoforms measured by an immunometric assay for choriocarcinoma-like hCG. The Journal of Endocrinology, 161, 99-106.
101. Birken, S. et al. (1988). Structure of the human chorionic gonadotropin betasubunit fragment from pregnancy urine. Endocrinology, 123, 572-583.
102. Blithe, D.L. et al. (1988). Purification of beta-core fragment from pregnancy urine and demonstration that its carbohydrate moieties differ from those of native human chorionic gonadotropin-beta. Endocrinology, 122, 173-180.
103. Blithe, D.L., Wehmann, R.E. and Nisula, B.C. (1989). Carbohydrate composition of beta-core. Endocrinology, 125, 2267-2272.
104. Birken, S. et al. (1993). Separation of nicked human chorionic gonadotropin (hCG), intact hCG, and hCG beta fragment from standard reference preparations and raw urine samples. Endocrinology, 133, 1390-1397.
105. Birken, S., Kovalevskaya, G. and O'Connor, J. (2001). Immunochemical measurement of early pregnancy isoforms of HCG: potential applications to fertility research, prenatal diagnosis, and cancer. Archives of Medical Research, 32, 635-643.
106. Iles, R.K. et al. (1992). Immunoreactive beta-core-like material in normal postmenopausal urine: human chorionic gonadotrophin orLHorigin? Evidence for the existence of LH core. The Journal of Endocrinology, 133, 459-466.
107. Birken, S. et al. (1993). Structure and significance of human luteinizing hormone-beta core fragment purified from human pituitary extracts. Endocrinology, 133, 985-989.
108. Neven, P. et al. (1993). Substantial urinary concentrations of material resembling beta-core fragment of chorionic gonadotropin beta-subunit in midmenstrual cycle. Clinical Chemistry, 39, 1857-1860.
109. O'Connor, J.F. et al. (1998). The expression of the urinary forms of human luteinizing hormone beta fragment in various populations as assessed by a specific immunoradiometric assay. Human Reproduction, 13, 826-835.
110. Thotakura, N.R. and Blithe, D.L. (1995). Glycoprotein hormones: glycobiology of gonadotrophins, thyrotrophin and free alpha subunit. Glycobiology, 5, 3-10.
111. Diaz-Cueto, L. et al. (1996). More in-vitro bioactive, shorter-lived human chorionic gonadotrophin charge isoforms increase at the end of the first and during the third trimesters of gestation. Molecular Human Reproduction, 2, 643-650.
112. Diaz-Cueto, L. et al. (1994). Amplitude regulation of episodic release, in vitro biological to immunological ratio, and median charge of human chorionic gonadotropin in pregnancy. The Journal of Clinical Endocrinology and Metabolism, 78, 890-897.
113. Wide, L. and Hobson, B. (1987). Some qualitative differences of hCG in serum from early and late pregnancies and trophoblastic diseases. Acta Endocrinologica, 116, 465-472.
114. Wide, L., Lee, J.Y. and Rasmussen, C. (1994). Achange in the isoforms of human chorionic gonadotropin occurs around the 13th week of gestation. The Journal of Clinical Endocrinology and Metabolism, 78, 1419-1423.
115. Skarulis, M.C. et al. (1992). Glycosylation changes in human chorionic gonadotropin and free alpha subunit as gestation progresses. The Journal of Clinical Endocrinology and Metabolism, 75, 91-96.
116. Cole, L.A. (1987). O-Glycosylation of proteins in the normal and neoplastic trophoblast. Trophoblast Research, 2, 139-148.
117. Cole, L.A. and Khanlian, S.A. (2007) Hyperglycosylated hCG: a variant with separate biological functions to regular hCG. Molecular and Cellular Endocrinology, 260-262, 228-236.
118. Cole, L.A. et al. (2003). Hyperglycosylated hCG (invasive trophoblast antigen, ITA) a key antigen for early pregnancy detection. Clinical Biochemistry, 36, 647-655.
119. Cole, L.A. et al. (2006). Hyperglycosylated hCG in gestational implantation and in choriocarcinoma and testicular germ cell malignancy tumorigenesis. The Journal of Reproductive Medicine, 51, 919-929.
120. Toll, H. et al. (2006). Glycosylation patterns of human chorionic gonadotropin revealed by liquid chromatography-mass spectrometry and bioinformatics. Electrophoresis, 27, 2734-2746.
121. Kobata, A. and Takeuchi, M. (1999). Structure, pathology and function of the N-linked sugar chains of human chorionic gonadotropin. Biochimica et Biophysica Acta, 1455, 315-326.
122. Bishop, L.A. et al. (1994). Specific roles for the asparagine-linked carbohydrate residues of recombinant human follicle stimulating hormone in receptor binding and signal transduction. Molecular Endocrinology, 8, 722-731.
123. Muyan, M. and Boime, I. (1998). The carboxyl-terminal region is a determinant for the intracellular behavior of the chorionic gonadotropin beta subunit: effects on the processing of the Asnlinked oligosaccharides. Molecular Endocrinology, 12, 766-772.
124. Sairam, M.R. (1989). Role of carbohydrates in glycoprotein hormone signal transduction. FASEB Journal, 3, 1915-1926.
125. Sairam, M.R. and Bhargavi, G.N. (1985). A role for glycosylation of the alpha subunit in transduction of biological signal in glycoprotein hormones. Science, 229, 65-67.
126. Smith, P.L. et al. (1990). The sialylated oligosaccharides of recombinant bovine lutropin modulate hormone bioactivity. The Journal of Biological Chemistry, 265, 874-881.
127. Dias, J.A. (2001). Is there any physiological role for gonadotrophin oligosaccharide heterogeneity in humans? II. A biochemical point of view. Human Reproduction, 16, 825-830.
128. Merz, W.E. (1988). Evidence for impaired subunit interaction in chemically deglycosylated human choriogonadotropin. Biochemical and Biophysical Research Communications, 156, 1271-1278.
129. Ryan, R.J. et al. (1987). Structure-function relationships of gonadotropins. Recent Progress in Hormone Research, 43, 383-429.
130. Huth, J.R. et al. (1994). Bacterial expression and in vitro folding of the betasubunit of human chorionic gonadotropin (hCG beta) and functional assembly of recombinant hCG beta with hCG alpha. Endocrinology, 135, 911-918.
131. Ren, P., Sairam, M.R. and Yarney, T.A. (1995). Bacterial expression of human chorionic gonadotropin alpha subunit: studies on refolding, dimer assembly and interaction with two different beta subunits. Molecular and Cellular Endocrinology, 113, 39-51.
132. Feng, W. et al. (1995). Asparagine-linked oligosaccharides facilitate human chorionic gonadotropin beta-subunit folding but not assembly of prefolded beta with alpha. Endocrinology, 136, 52-61.
133. Feng, W. et al. (1995). The asparaginelinked oligosaccharides of the human chorionic gonadotropin beta subunit facilitate correct disulfide bond pairing. The Journal of Biological Chemistry, 270, 11851-11859.
134. Feng, W. et al. (1996). Novel covalent chaperone complexes associated with human chorionic gonadotropin beta subunit folding intermediates. The Journal of Biological Chemistry, 271, 18543-18548.
135. Flack, M.R. et al. (1994). Site-directed mutagenesis defines the individual roles of the glycosylation sites on folliclestimulating hormone. The Journal of Biological Chemistry, 269, 14015-14020.
136. Ulloa-Aguirre, A. et al. (1992). Effects of gonadotrophin-releasing hormone, recombinant human activin-A and sex steroid hormones upon the folliclestimulating isohormones secreted by rat anterior pituitary cells in culture. The Journal of Endocrinology, 134, 97-106.
137. Blithe, D.L. and Iles, R.K. (1995). The role of glycosylation in regulating the glycoprotein hormone free alpha-subunit and free beta-subunit combination in the extraembryonic coelomic fluid of early pregnancy. Endocrinology, 136, 903-910.
138. Morell, A.G. et al. (1971). The role of sialic acid in determining the survival of glycoproteins in the circulation. The Journal of Biological Chemistry, 246, 1461-1467.
139. Lefort, G.P., Stolk, J.M. and Nisula, B.C. (1984). Evidence that desialylation and uptake by hepatic receptors for galactoseterminated glycoproteins are immaterial to the metabolism of human choriogonadotropin in the rat. Endocrinology, 115, 1551-1557.
140. Nisula, B.C. et al. (1989). Metabolic fate of human choriogonadotropin. Journal of Steroid Biochemistry, 33, 733-737.
141. Barrios-De-Tomasi, J. et al. (2002). Assessment of the in vitro and in vivo biological activities of the human folliclestimulating isohormones. Molecular and Cellular Endocrinology, 186, 189-198.
142. Ulloa-Aguirre, A. et al. (1992). Biological characterization of the naturally occurring analogues of intrapituitary human follicle-stimulating hormone. Human Reproduction, 7, 23-30.
143. Wide, L. (1986). The regulation of metabolic clearance rate of human FSH in mice by variation of the molecular structure of the hormone. Acta Endocrinologica, 112, 336-344.
144. Fiete, D. and Baenziger, J.U. (1997). Isolation of the SO4-4-GalNAcbeta1,4GlcNAcbeta1,2Manalphaspecific receptor from rat liver. The Journal of Biological Chemistry, 272, 14629-14637.
145. Fiete, D. et al. (1991). A hepatic reticuloendothelial cell receptor specific for SO4-4GalNAc beta 1,4GlcNAc beta 1,2Man alpha that mediates rapid clearance of lutropin. Cell, 67, 1103-1110.
146. Klett, D. et al. (2003) Fast renal trapping of porcine luteinizing hormone (pLH) shown by 123I-scintigraphic imaging in rats explains its short circulatory half-life. Reproductive Biology and Endocrinology, 1, 64.
147. Legardinier, S. et al. (2005). Biological activities of recombinant equine luteinizing hormone/chorionic gonadotropin (eLH/CG) expressed in Sf9 and Mimic insect cell lines. Journal of Molecular Endocrinology, 34, 47-60.
148. Legardinier, S. et al. (2005). Mammalianlike nonsialyl complex-type Nglycosylation of equine gonadotropins in Mimic insect cells. Glycobiology, 15, 776-790.
149. Duijkers, I.J. et al. (2002). Single dose pharmacokinetics and effects on follicular growth and serum hormones of a longacting recombinant FSH preparation (FSH-CTP) in healthy pituitarysuppressed females. Human Reproduction, 17, 1987-1993.
150. Bouloux, P.M. et al. (2001). First human exposure to FSH-CTP in hypogonadotrophic hypogonadal males. Human Reproduction, 16, 1592-1597.
151. Perlman, S. et al. (2003). Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone. The Journal of Clinical Endocrinology and Metabolism, 88, 3227-3235.
152. Weenen, C. et al. (2004). Long-acting follicle-stimulating hormone analogs containing N-linked glycosylation exhibited increased bioactivity compared with o-linked analogs in female rats. The Journal of Clinical Endocrinology and Metabolism, 89, 5204-5212.
153. Sharpless, J.L. et al. (1999). Disappearance of endogenous luteinizing hormone is prolonged in postmenopausal women. The Journal of Clinical Endocrinology and Metabolism, 84, 688-694.
154. Wide, L. et al. (2007). Sulfonation and sialylation of gonadotropins in women during the menstrual cycle, after menopause, and with polycystic ovarian syndrome and in men. The Journal of Clinical Endocrinology and Metabolism, 92, 4410-4417.
155. West, C.R. et al. (2002). Acidic mix of FSH isoforms are better facilitators of ovarian follicular maturation and E2 production than the less acidic. Endocrinology, 143, 107-116.
156. Matzuk, M.M., Keene, J.L. and Boime, I. (1989). Site specificity of the chorionic gonadotropin N-linked oligosaccharides in signal transduction. The Journal of Biological Chemistry, 264, 2409-2414.
157. Valove, F.M. et al. (1994). Receptor binding and signal transduction are dissociable functions requiring different sites on follicle-stimulating hormone. Endocrinology, 135, 2657-2661.
158. Bousfield, G.R. et al. (2004). Differential effects of alpha subunit asparagine56 oligosaccharide structure on equine lutropin and follitropin hybrid conformation and receptor-binding activity. Biochemistry, 43, 10817-10833.
159. Rebois, R.V. and Liss, M.T. (1987). Antibody binding to the beta-subunit of deglycosylated chorionic gonadotropin converts the antagonist to an agonist. The Journal of Biological Chemistry, 262, 3891-3896.
160. Butney, V.Y. et al. (1998). Hormonespecific inhibitory influence of alphasubunit Asn56 oligosaccharide on in vitro subunit association and folliclestimulating hormone receptor binding of equine gonadotropins. Biology of Reproduction, 58, 458-469.
161. Heikoop, J.C. et al. (1998). Partially deglycosylated human choriogonadotropin, stabilized by intersubunit disulfide bonds, shows full bioactivity. European Journal of Biochemistry, 253, 354-356.
162. Butnev, V.Y. et al. (2002). Truncated equine LH beta and asparagine(56)- deglycosylated equine LH alpha combine to produce a potent FSH antagonist. The Journal of Endocrinology, 172, 545-555.
163. Fan, Q.R. and Hendrickson, W.A. (2005). Structural biology of glycoprotein hormones and their receptors. Endocrine, 26, 179-188.
164. Arey, B.J. et al. (1997). Induction of promiscuous G protein coupling of the follicle-stimulating hormone (FSH) receptor: a novel mechanism for transducing pleiotropic actions of FSH isoforms. Molecular Endocrinology, 11, 517-526.
165. Andersen, C.Y. et al. (2001). Effect of different FSH isoforms on cyclic-AMP production by mouse cumulus-oocytecomplexes: a time course study. Molecular Human Reproduction, 7, 129-135.
166. Barrios-de-Tomasi, J. et al. (2006). Effects of human pituitary FSH isoforms on mouse follicles in vitro. Reproductive Biomedicine Online, 12, 428-441.
167. Timossi, C.M. et al. (1998). A naturally occurring basically charged human follicle-stimulating hormone (FSH) variant inhibits FSH-induced androgen aromatization and tissue-type plasminogen activator enzyme activity in vitro. Neuroendocrinology, 67, 153-163.
168. Timossi, C.M. et al. (2000). Differential effects of the charge variants of human follicle-stimulating hormone. The Journal of Endocrinology, 165, 193-205.
169. Creus, S. et al. (2001). Human FSH isoforms: carbohydrate complexity as determinant of in-vitro bioactivity. Molecular and Cellular Endocrinology, 174, 41-49.
170. Stanton, P.G. et al. (1993). Isolation and characterization of human LH isoforms. The Journal of Endocrinology, 138, 529-543.
171. Stanton, P.G. et al. (1992). Isolation and physicochemical characterization of human follicle-stimulating hormone isoforms. Endocrinology, 130, 2820-2832.
172. Reddy, B.V., Bartoszewicz, Z. and Rebois, R.V. (1996). Modification of the sialic acid residues of choriogonadotropin affects signal transduction. Cellular Signalling, 8, 35-41.
173. Kovalevskaya, G. et al. (2002). Trophoblast origin of hCG isoforms: cytotrophoblasts are the primary source of choriocarcinoma-like hCG. Molecular and Cellular Endocrinology, 194, 147-155.
174. Kovalevskaya, G. et al. (2002). Differential expression of human chorionic gonadotropin (hCG) glycosylation isoforms in failing and continuing pregnancies: preliminary characterization of the hyperglycosylated hCG epitope. The Journal of Endocrinology, 172, 497-506.
175. Cole, L.A. et al. (2006). Gestational trophoblastic diseases: 1. Pathophysiology of hyperglycosylated hCG. Gynecologic Oncology, 102, 145-150.
176. Lei, Z.M. et al. (1999). Human chorionic gonadotropin promotes tumorigenesis of choriocarcinoma JAR cells. Trophoblast Research, 13, 147-159.
177. Hamada, A.L. et al. (2005). Transfection of antisense chorionic gonadotropin beta gene into choriocarcinoma cells suppresses the cell proliferation and induces apoptosis. The Journal of Clinical Endocrinology and Metabolism, 90, 4873-4879.
178. Cole, L.A. et al. (1988). Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers. Cancer Research, 48, 1356-1360.
179. Lundin, M. et al. (2001). Tissue expression of human chorionic gonadotropin beta predicts outcome in colorectal cancer: a comparison with serum expression. International Journal of Cancer, 95, 18-22.
180. Mora, J. et al. (1996). Different hCG assays to measure ectopic hCG secretion in bladder carcinoma patients. British Journal of Cancer, 74, 1081-1084.
181. Hotakainen, K. et al. (1999). Detection of messenger RNA for the beta-subunit of chorionic gonadotropin in urinary cells from patients with transitional cell carcinoma of the bladder by reverse transcription-polymerase chain reaction. International Journal of Cancer, 84, 304-308.
182. Hotakainen, K. et al. (2007). Overexpression of human chorionic gonadotropin beta genes 3, 5 and 8 in tumor tissue and urinary cells of bladder cancer patients. Tumour Biology: The Journal of the International Society, for Oncodevelopmental Biology and Medicine 28, 52-56.
183. Yokotani, T. et al. (1997). Expression of alpha and beta genes of human chorionic gonadotropin in lung cancer. International Journal of Cancer, 71, 539-544.
184. Liu, T.C. and Jackson, G.L. (1990). 17-Betaestradiol potentiates luteinizing hormone glycosylation and release induced by veratridine, diacylglycerol, and phospholipase C in rat anterior pituitary cells. Neuroendocrinology, 51, 642-648.
185. Wide, L. and Naessen, T. (1994). 17 Betaoestradiol counteracts the formation of the more acidic isoforms of folliclestimulating hormone and luteinizing hormone after menopause. Clinical Endocrinology, 40, 783-789.
186. Bergendah, M. and Veldhuis, J.D. (2001). Is there a physiological role for gonadotrophin oligosaccharide heterogeneity in humans? III. Luteinizing hormone heterogeneity: a medical physiologist's perspective. Human Reproduction, 16, 1058-1064.
187. Wide, L. (1982). Male and female forms of human follicle-stimulating hormone in serum. The Journal of Clinical Endocrinology and Metabolism, 55, 682-688.
188. Castro-Fernandez, C. et al. (2000). A preponderance of circulating basic isoforms is associated with decreased plasma half-life and biological to immunological ratio of gonadotropinreleasing hormone-releasable luteinizing hormone in obese men. The Journal of Clinical Endocrinology and Metabolism, 85, 4603-4610.
189. Tsatsoulis, A., Shalet, S.M. and Robertson, W.R. (1988). Changes in the qualitative and quantitative secretion of luteinizing hormone (LH) following orchidectomy in man. Clinical Endocrinology, 29, 189-194.
190. Campo, S. et al. (2007) Carbohydrate complexity and proportions of serum FSH isoforms in the male: lectin-based studies. Molecular and Cellular Endocrinology, 260-262, 197-204.
191. Weintraub, B.D. et al. (1989). Effect of TRH on TSH glycosylation and biological action. Annals of the New York Academy of Sciences, 553, 205-213.
192. Weintraub, B.D. et al. (1990). Pretranslational and post-translational regulation of TSH: relationship to bioactivity. Hormone and Metabolic Research. Supplement, 23, 9-11.
193. Khan, S.A. et al. (1985). Influence of gonadectomy on isoelectrofocusing profiles of pituitary gonadotropins in rhesus monkeys. Journal of Medical Primatology, 14, 177-194.
194. Solano, A.R. et al. (1980). Modulation of serum and pituitary luteinizing hormone bioactivity by androgen in the rat. Endocrinology, 106, 1941-1948.
195. Christianson, S.L., Zalesky, D.D. and Grotjan, H.E. (1998). Ovine luteinizing hormone heterogeneity: androgens increase the percentage of less basic isohormones. Domestic Animal Endocrinology, 15, 87-92.
196. Mitchell, R. et al. (1994). Less acidic forms of luteinizing hormone are associated with lower testosterone secretion in men on haemodialysis treatment. Clinical Endocrinology, 41, 65-73.
197. Sharma, O.P. et al. (1990). Effects of androgens on bioactivity and immunoreactivity of pituitary FSH in GnRH antagonist-treated male rats. Acta Endocrinologica, 122, 168-174.
198. Kennedy, J. and Chappel, S. (1985). Direct pituitary effects of testosterone and luteinizing hormone-releasing hormone upon follicle-stimulating hormone: analysis by radioimmuno- and radioreceptor assay. Endocrinology, 116, 741-748.
199. Helton, T.E. and Magner, J.A. (1994). Beta-1,4-galactosyltransferase and alphamannosidase-II messenger ribonucleic acid levels increase with different kinetics in thyrotrophs of hypothyroid mice. Endocrinology, 135, 1980-1985.
200. Helton, T.E. and Magner, J.A. (1994). Sialyltransferase messenger ribonucleic acid increases in thyrotrophs of hypothyroid mice: an in situ hybridization study. Endocrinology, 134, 2347-2353.
201. Helton, T.E. and Magner, J.A. (1995). Betagalactoside alpha-2,3-sialyltransferase messenger RNA increases in thyrotrophs of hypothyroid mice. Thyroid, 5, 315-317.
202. Persani, L. et al. (1998). Changes in the degree of sialylation of carbohydrate chains modify the biological properties of circulating thyrotropin isoforms in various physiological and pathological states. The Journal of Clinical Endocrinology and Metabolism, 83, 2486-2492.
203. Trojan, J. et al. (1998). Modulation of human thyrotropin oligosaccharide structures-enhanced proportion of sialylated and terminally galactosylated serum thyrotropin isoforms in subclinical and overt primary hypothyroidism. The Journal of Endocrinology, 158, 359-365.
204. Persani, L. et al. (2000). Circulating thyrotropin bioactivity in sporadic central hypothyroidism. The Journal of Clinical Endocrinology and Metabolism, 85, 3631-3635.
205. DeCherney, G.S. et al. (1989). Alterations in the sialylation and sulfation of secreted mouse thyrotropin in primary hypothyroidism. Biochemical and Biophysical Research Communications, 159, 755-762.
206. Gyves, P.W. et al. (1990). Changes in the sialylation and sulfation of secreted thyrotropin in congenital hypothyroidism. Proceedings of the National Academy of Sciences of the United States of America 87, 3792-3796.
207. Simoni, M. et al. (1996). Effects of gonadotropin-releasing hormone on bioactivity of follicle-stimulating hormone (FSH) and microstructure of FSH, luteinizing hormone and sex hormone-binding globulin in a testosterone-based contraceptive trial: evaluation of responders and nonresponders. European Journal of Endocrinology/European Federation of, Endocrine Societies 135, 433-439.
208. Zarinan, T. et al. (2001). Changes in the biological:immunological ratio of basal and GnRH-releasable FSH during the follicular, pre-ovulatory and luteal phases of the human menstrual cycle. Human Reproduction, 16, 1611-1618.
209. Ebling, F.J. et al. (1990). Metabolic interfaces between growth and reproduction. III. Central mechanisms controlling pulsatile luteinizing hormone secretion in the nutritionally growthlimited female lamb. Endocrinology, 126, 2719-2727.
210. Hassing, J.M. et al. (1993). Pulsatile administration of gonadotropin-releasing hormone does not alter the folliclestimulating hormone (FSH) isoform distribution pattern of pituitary or circulating FSH in nutritionally growthrestricted ovariectomized lambs. Endocrinology, 132, 1527-1536.
211. Liu, T.C., Jackson, G.L. and Gorski, J. (1976). Effects of synthetic gonadotropinreleasing hormone on incorporation of radioactive glucosamine and amino acids into luteinizing hormone and total protein by rat pituitaries in vitro. Endocrinology, 98, 151-163.
212. Khar, A., Debeljuk, L., Jutisz, M. (1978). Biosynthesis of gonadotropins by rat pituitary cells in culture and in pituitary homogenates: effect of gonadotropinreleasing hormone. Molecular and Cellular Endocrinology, 12, 53-65.
213. Baird, D.T. (2001). Is there a place for different isoforms of FSH in clinical medicine? IV. The clinician's point of view. Human Reproduction, 16, 1316-1318.
214. Lunenfeld, B. (2004). Historical perspectives in gonadotrophin therapy. Human Reproduction Update, 10, 453-467.
215. Talbot, J.A. et al. (1996). Recombinant human luteinizing hormone: a partial physicochemical, biological and immunological characterization. Molecular Human Reproduction, 2, 799-806.
216. Gervais, A. et al. (2003). Glycosylation of human recombinant gonadotrophins: characterization and batch-to-batch consistency. Glycobiology, 13, 179-189.
217. Horsman, G. et al. (2000). A biological, immunological and physico-chemical comparison of the current clinical batches of the recombinant FSH preparations Gonal-F and Puregon. Human Reproduction, 15, 1898-1902.
218. van Wely, M. et al. (2003). Effectiveness of human menopausal gonadotropin versus recombinant follicle-stimulating hormone for controlled ovarian hyperstimulation in assisted reproductive cycles: a meta-analysis. Fertility and Sterility, 80, 1086-1093.
219. Van Wely, M. et al. (2003) Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews, 1, CD003973.
220. Ledger, W. (2005) Clinical pharmacology of gonadotrophin preparations. Reproductive Biomedicine Online, 10 (Suppl. 3), 19-24.
221. Coomarasamy, A. et al. (2008). Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long downregulation protocol in IVF or ICSI treatment: a systematic review and metaanalysis. Human Reproduction, 23, 310-315.
222. Lambert, A. et al. (1998). Gonadotrophin heterogeneity and biopotency: implications for assisted reproduction. Molecular Human Reproduction, 4, 619-629.
223. Hard, K. et al. (1990). Isolation and structure determination of the intact sialylated N-linked carbohydrate chains of recombinant human follitropin expressed in Chinese hamster ovary cells. European Journal of Biochemistry, 193, 263-271.
224. Rafferty, B. et al. (1995). Differences in carbohydrate composition of FSH preparations detected with lectin-ELISA systems. The Journal of Endocrinology, 145, 527-533.
225. Amoresano, A. et al. (1996). Structural characterisation of human recombinant glycohormones follitropin, lutropin and choriogonadotropin expressed in Chinese hamster ovary cells. European Journal of Biochemistry, 242, 608-618.
226. Flack, M.R. et al. (1994). Increased biological activity due to basic isoforms in recombinant human follicle-stimulating hormone produced in a human cell line. The Journal of Clinical Endocrinology and Metabolism, 79, 756-760.
227. Phillip, M. et al. (1998). Male hypogonadism due to a mutation in the gene for the beta-subunit of folliclestimulating hormone. The New England Journal of Medicine, 338, 1729-1732.
228. Depenbusch, M. et al. (2002). Maintenance of spermatogenesis in hypogonadotropic hypogonadal men with human chorionic gonadotropin alone. European Journal of Endocrinology/European Federation of, Endocrine Societies 147, 617-624.
229. Finkel, D.M., Phillips, J.L. and Snyder, P.J. (1985). Stimulation of spermatogenesis by gonadotropins in men with hypogonadotropic hypogonadism. The New England Journal of Medicine, 313, 651-655.
230. Kliesch, S., Behre, H.M. and Nieschlag, E. (1995). Recombinant human folliclestimulating hormone and human chorionic gonadotropin for induction of spermatogenesis in a hypogonadotropic male. Fertility and Sterility, 63, 1326-1328.
231. Liu, P.Y. et al. (1999). Efficacy and safety of recombinant human follicle stimulating hormone (Gonal-F) with urinary human chorionic gonadotrophin for induction of spermatogenesis and fertility in gonadotrophin-deficient men. Human Reproduction, 14, 1540-1545.
232. Jablonka-Shariff, A. et al. (2006). Singlechain, triple-domain gonadotropin analogs with disulfide bond mutations in the alpha-subunit elicit dual follitropin and lutropin activities in vivo. Molecular Endocrinology, 20, 1437-1446.
233. Garone, L.M. et al. (2006). Biological properties of a novel follicle-stimulating hormone/human chorionic gonadotropin chimeric gonadotropin. Endocrinology, 147, 4205-4212.
234. Agrawal, R. et al. (1997). Pregnancy after treatment with three recombinant gonadotropins. Lancet, 349, 29-30.
235. Macklon, N.S. and Fauser, B.C. (2002). Gonadotropin therapy for the treatment of anovulation and for ovarian hyperstimulation for IVF. Molecular and Cellular Endocrinology, 186, 159-161.
236. Macklon, N. (2005) Gonadotrophins in ovulation induction. Reproductive Biomedicine Online, 10 (Suppl. 3), 25-31.
237. Balen, A. et al. (2007). Highly purified FSH is as efficacious as recombinant FSH for ovulation induction in women withWHO Group II anovulatory infertility: a randomized controlled non-inferiority trial. Human Reproduction, 22, 1816-1823.
238. Macklon, N.S. and Fauser, B.C. (2001). Follicle-stimulating hormone and advanced follicle development in the human. Archives of Medical Research, 32, 595-600.
239. Fauser, B.C., Devroey, P. and Macklon, N.S. (2005). Multiple birth resulting from ovarian stimulation for subfertility treatment. Lancet, 365, 1807-1816.
240. Macklon, N.S. et al. (2006). The science behind 25 years of ovarian stimulation for in vitro fertilization. Endocrine Reviews, 27, 170-207.
241. Group, E.R.L.S. (2001). Human recombinant luteinizing hormone is as effective as, but safer than, urinary human chorionic gonadotropin in inducing final follicular maturation and ovulation in in vitro fertilization procedures: results of a multicenter double-blind study. The Journal of Clinical Endocrinology and Metabolism, 86, 2607-2618.
242. Chang, P. et al. (2001). Recombinant human chorionic gonadotropin (rhCG) in assisted reproductive technology: results of a clinical trial comparing two doses of rhCG (Ovidrel) to urinary hCG (Profasi) for induction of final follicular maturation in in vitro fertilizationembryo transfer. Fertility and Sterility, 76, 67-74.
243. Piani, D. and Malkowski, J.P. (2001). Recombinant hCG (OVIDREL) and recombinant interferon-beta1a (REBIF) (No. 13 in a series of articles to promote a better understanding of the use of genetic engineering). Journal of Biotechnology, 87, 281-283.
244. The European Recombinant Human Chorionic Gonadotropin Study Group (2000) Induction of final follicular maturation and early luteinization in women undergoing ovulation induction for assisted reproduction treatment-recombinant HCG versus urinary HCG. Human Reproduction, 15, 1446-1451.
245. Lathi, R.B. and Milki, A.A. (2001). Recombinant gonadotropins. Current Women's Health Reports, 1, 157-163.
246. Lispi, M. et al. (2006). Comparative assessment of the consistency and quality of a highly purified FSH extracted from human urine (urofollitropin) and a recombinant human FSH (follitropin alpha). Reproductive Biomedicine Online, 13, 179-193.
247. Durnerin, C.I. et al. (2008). Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Human Reproduction, 23, 421-426.
248. Nyboeandersen, A. et al. (2008). Recombinant LH supplementation to recombinant FSH during the final days of controlled ovarian stimulation for in vitro fertilization. A multicentre, prospective, randomized, controlled trial. Human Reproduction, 23, 427-434.
249. Mochtar, M.H. et al. (2007) Recombinant luteinizing hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database of Systematic Reviews, 2, CD005070.
250. Kaufmann, R. et al. (2007). Recombinant human luteinizing hormone, lutropin alfa, for the induction of follicular development and pregnancy in profoundly gonadotrophin-deficient women. Clinical Endocrinology, 67, 563-569.
251. Beckers, N.G. et al. (2003). First live birth after ovarian stimulation using a chimeric long-acting human recombinant follicle-stimulating hormone (FSH) agonist (recFSH-CTP) for in vitro fertilization. Fertility and Sterility, 79, 621-623.
252. Klein, J. et al. (2003). Development and characterization of a long-acting recombinant hFSH agonist. Human Reproduction, 18, 50-56.
253. Bernard, M.P. et al. (2005). Crosslinked bifunctional gonadotropin analogs with reduced efficacy. Molecular and Cellular Endocrinology, 233, 25-31.